Testimony Before the FDA’s Psychopharmacologic Drugs Advisory Committee Regarding Pimavanserin for the Treatment of Hallucinations and Delusions in Alzheimer’s Disease Psychosis

View as PDF

In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Psychopharmacologic Drugs Advisory Committee, Public Citizen urged the committee to recommend that the FDA not approve pimavanserin for the treatment of hallucinations and delusions in Alzheimer’s disease psychosis because clinical trials of the drug failed to demonstrate that it is effective.